The Medical Epigenomics Lab is part of the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences. The lab is directed by Christoph Bock, who is a Principal Investigator at CeMM and a Guest Professor in Medical University of Vienna's Department of Laboratory Medicine. He is a member of the European BLUEPRINT project contributing to the work of the International Human Epigenome Consortium to map 1,000 reference epigenomes, and he the project leader of Genom Austria (which is the Austrian member in the International Network of Personal Genome Projects).

The lab's scientific goal is to improve cancer therapy through technology-driven research on the single-cell characterization, computational modeling, and rational reprogramming of the cancer epigenome. An interdisciplinary team of wet-lab and computational researchers combines wet-lab epigenetics research, bioinformatics modeling, and high-throughput sequencing - usually with a translational component and in collaboration with clinical researchers.

Research Topics

  • Epigenomics. We perform large-scale epigenome mapping to dissect the dynamics of cancer development and drug resistance. This work is integrated with the BLUEPRINT project and the International Human Epigenome Consortium.
  • Technology. Exciting biomedical research is often driven by new technologies. Our lab is therefore heavily invested into technology development, including single-cell protocols, nanopore sequencing, CRISPR, and epigenome editing.
  • Bioinformatics. New algorithms and computational methods allow us to accurately infer epigenetic cell states from large-scale datasets, in order to reconstruct the epigenetic landscape that controls cellular differentiation and reprogramming.
  • Diagnostics. Using large-scale DNA methylation mapping, bioinformatic prioritization, and functional characterization, we strive to develop clinically relevant biomarkers for informing personalized cancer therapy.

Key Publications

joomla 1.6 templates free